Exposure to modifiable lifestyle and environmental risk factors accounts for approximately 40% of all cancers in the UK. Therefore, primary prevention is of growing importance and an effective and engaging strategy that encourages long-term adoption of healthy lifestyle behaviours is required.

Several multivariable risk prediction models have been developed to assess an individual's risk of developing specific cancers. Such models can be used in a variety of settings for prevention, screening, and guiding investigation and treatment. Models aimed at predicting future disease risk that contains modifiable factors may be of particular use for targeting health promotion activities at an individual level. We have therefore developed a UK version of the well-established U.S. derived “YourDiseaseRisk” model which allow users to quantify their individual risk of developing individual cancers relative to the population average risk.

The UK-Manchester version of “YourDiseaseRisk” computes 10 year cancer risk for 11 cancer types utilising UK figures for prevalence of risk factors and cancer incidence. The model can be used to estimate cancer risk for use in community settings.

Using a variety of qualitative and quantitative methods we have assessed the impact of the REFLECT risk model on public understanding of cancer risk factors and UK NHS Cancer Screening programs. We have also explored public opinion and perceptions regarding the provision of information on of genetic susceptibility to aid in further personalising cancer risk information.

This abstract is also being presented as PosterB10.

Citation Format: Artitaya Lophatananon, Kawthar Alajmi, Emma Thorpe, John Hughes, Joanna Blodgett, Bernadette Fisher, Simon Rogers, Erika K. Waters, Kenneth R. Muir. Development of a cancer risk prediction tool for use in the Risk Estimation For Lifestyle Enhancement Combined Trial (REFLECT). [abstract]. In: Proceedings of the AACR Special Conference: Improving Cancer Risk Prediction for Prevention and Early Detection; Nov 16-19, 2016; Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(5 Suppl):Abstract nr PR14.